Tempus AI earnings release, July 30, 2026

Tempus AI, Inc. (TEM) · Form 8-K, Item 2.02 · Filed · SEC filing

Tempus Reports Second Quarter 2026 Results

CHICAGO, July 30, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, 2026.

“Q2 was another exceptional quarter for us,” said Eric Lefkofsky, Founder and CEO of Tempus. “Our strategy is working given the investments we have made in AI over the past several years are driving some of the best growth rates we have seen in our two largest businesses - Oncology Diagnostics and Data Licensing.”

Second Quarter 2026 Highlights

• Total revenue of $382.5 million, up 22% year-over-year

• Oncology volume growth of 31% year-over-year, up from 28% last quarter

• Molecular residual disease (MRD) volume was 9,000 tests, up from 6,500 last quarter

• Data Licensing & Modeling (Insights) revenue up 36% year-over-year

• Signed ~$200 million in new Data and Applications licenses

• FDA approved xT Tumor Only which will migrate tissue testing to ADLT pricing

• Successfully delivered our first oncology foundation model to AstraZeneca

• Completed a $460 million offering of 0.0% convertible senior notes due 2032

• GAAP net income of $5.6 million and Adjusted EBITDA of $8.0 million

• Cash and marketable securities of $820.7 million as of June 30, 2026

• Increasing revenue guidance to $1.595 to $1.605 billion for 2026 and expect full year Adjusted EBITDA of ~$65 million

On July 20, 2026, Tempus also announced an agreement to acquire Personalis, a leader in the tumor-informed MRD space. “Through our existing collaboration with Personalis, we have already demonstrated the strength of combining highly sensitive MRD technology with our commercial infrastructure,” said Mr. Lefkofsky. “With clinical adoption and reimbursement momentum building, we believe we are collectively well positioned to capture this opportunity, which makes this acquisition particularly exciting.”

Second Quarter 2026 Summary Results

• Revenue increased 22% year-over-year to $382.5 million.

• Diagnostics generated $289.3 million of revenue, representing 20% year-over-year growth, driven by Oncology volume growth of 31%, offset by Hereditary revenue growth of 5%.

• Data and Applications generated $93.2 million of revenue, representing 28% year-over-year growth, with Insights growing 36%.

• Gross profit increased 26% year-over-year to $246.5 million, led by growth in Data and Applications.

• Net income was $5.6 million, which included $55.6 million of stock compensation expense and related employer payroll taxes and $98.5 million in unrealized gains on marketable securities, compared to a net loss of $(42.8 million) in Q2 of 2025.

• Adjusted EBITDA was $8.0 million, compared to ($5.6 million) in Q2 of 2025.

• $820.7 million in cash and marketable securities as of June 30, 2026.

Recent Operational Highlights

• Entered into a definitive agreement to acquire Personalis for $16.25 per share (~$1.5 billion enterprise value), tightly integrating its ultrasensitive NeXT Personal® MRD technology into Tempus' diagnostic platform

• Received FDA approval for tumor-only xT CDx assay, becoming the first laboratory to hold FDA companion diagnostic (CDx) approval for both tumor-only and tumor-normal comprehensive genomic profiling

• Launched digital pathology IMS Open-Source Consortium along with Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK) to accelerate the democratization and standardization of digital pathology

• Introduced Tempus Preview to provide preliminary results for high impact biomarkers within ~24 hours of tissue receipt

• Announced a strategic collaboration with the Keck School of Medicine of USC to integrate Tempus' AI platform, molecular diagnostics, and clinical trial matching across more than 1.5 million annual patient visits to accelerate precision oncology care

• Introduced initial results from and successfully delivered the first version of our foundation model to AstraZeneca

• Signed large deals with BioNTech, Daiichi Sankyo, Level Set Bio, and Incyte Pharmaceuticals, contributing to ~$200 million in total bookings this quarter

Second Quarter Financial Results

Financial Outlook and Guidance

Tempus is increasing its full year 2026 revenue guidance to $1.595 to $1.605 billion, which represents ~25% annual growth. We continue to expect 2026 Adjusted EBITDA to be ~$65 million. Guidance assumes no impact from the Personalis transaction, which is expected to close in late Q4 2026 or early 2027.

For additional information on the quarter, including a letter from our CEO and CFO, please visit our investor relations site at investors.tempus.com.

Webcast and Conference Call Information

A conference call and webcast will begin today, July 30, 2026 after market close at 4:30 p.m. Eastern Time. Interested parties may access details at:

Conference ID: 9053038

United States - New York: (646) 307-1963

USA & Canada - Toll-Free: (800) 715-9871

Live webcast can be accessed here

The webcast may be accessed on the company’s investor relations website at investors.tempus.com. For those unable to listen to the live webcast, a recording will be made available on the company’s website after the event and will be accessible for one year. Visit the investor relations website to find the company’s latest deck, and commentary on the quarter by Eric Lefkofsky, Founder and CEO, and Jim Rogers, CFO, which will be discussed on the conference call and webcast.

About Tempus... (truncated)t and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Non-GAAP Financial Measures

In addition to the financial information presented in this release in accordance with accounting principles generally accepted in the United States of America (GAAP), Tempus also presents adjusted non-GAAP financial measures.

Non-GAAP gross profit is defined as GAAP gross profit, excluding stock-based compensation expense and employer payroll tax related to stock-based compensation (collectively, the “stock-based compensation adjustments”).

Non-GAAP gross margin is defined as gross profit, excluding the stock-based compensation adjustments, as a percentage of revenue.

Non-GAAP operating expenses are calculated as the sum of technology research and development expense, research and development expense, and selling, general and administrative expense, excluding the stock-based compensation adjustments, acquisition-related expenses, amortization of intangibles due to acquisition, and franchise taxes related to IPO.

Non-GAAP loss from operations is defined as loss from operations, adjusted to exclude (i) the stock-based compensation adjustments, (ii) acquisition-related expenses, (iii) franchise taxes related to IPO, and (iv) amortization of intangibles due to acquisition.

Non-GAAP net loss is defined as net income (loss), adjusted to exclude (i) changes in fair value of our marketable equity securities and indemnity-related holdback liabilities, (ii) the stock-based compensation adjustments, (iii) acquisition-related expenses, (iv) amortization of intangibles due to acquisition, (v) losses from equity method investments, (vi) provision for (benefit from) income taxes, (vii) franchise taxes related to IPO, and (viii) amortization of deferred other income from our IP License Agreement with SB Tempus, and (ix) loss on debt extinguishment.

Non-GAAP net loss per share is defined as non-GAAP net loss divided by weighted average common shares outstanding, basic.

Adjusted EBITDA is defined as net (income) loss, adjusted to exclude (i) interest income, (ii) interest expense, (iii) depreciation and amortization, (iv) provision for (benefit from) income taxes, (v) losses from equity method investments, (vi) changes in fair value of our marketable equity securities and indemnity-related holdback liabilities, (vii) the stock-based compensation adjustments, (viii) acquisition-related expenses, and (ix) amortization of deferred other income from our IP License Agreement with SB Tempus, (x) franchise taxes related to our IPO, and (xi) loss on debt extinguishment.

Tempus believes these non-GAAP financial measures are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making and they may be used by institutional investors and the analyst community to help them analyze the health of Tempus’ business. In particular, Adjusted EBITDA is a key measurement used by Tempus management to make operating decisions, including those related to analyzing operating expenses, evaluating performance, and performing strategic planning and annual budgeting. However, there are a number of limitations related to the use of non-GAAP financial measures, and these non-GAAP measures should be considered in addition to, not as a substitute for or in isolation from, our financial results prepared in accordance with GAAP. Other companies, including companies in our industry, may calculate these non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures.

Tempus does not provide guidance for net (income) loss, the most directly comparable GAAP measure to Adjusted EBITDA, and similarly cannot provide a reconciliation between Tempus’ forecasted Adjusted EBITDA and net loss without unreasonable effort due to the unavailability of reliable estimates for certain components of net loss and the respective reconciliations. These forecasted items are not within Tempus’ control, may vary greatly between periods, and could significantly impact future financial results.

Other Key Metrics

Total Remaining Contract Value (TCV) is equal to the total potential value of signed contracts and assumes the exercise of all contract options, all discretionary opt-ins, and no early termination. Remaining TCV excludes any revenue recognized to date on these contracts or any future adjustments made to the contractual value as a result of amendments or terminations.

Net Revenue Retention compares the annual Insights product revenue generated from all customers that made an Insights purchase in one year to the annual Insights product revenue generated from the same cohort of customers in the subsequent year.

Financial statements

Income Statement

Three Months Ended June 30, — Second Quarter Financial Results (in thousands, except percentages and per share amounts)

Three Months Ended June 30, – 2026 – (unaudited)Three Months Ended June 30, – 2025 – (unaudited)Change
Revenue382,486314,63522.0%
Gross profit246,498195,03926.0%
Loss from operations-75,913-61,77423.0%
Non-GAAP loss from operations-2,708-17,036-84.0%
Net income (loss)5,642-42,843113.0%
Non-GAAP net loss-7,726-37,327-79.0%
Adjusted EBITDA8,044-5,580244.0%
Net income (loss) per share, basic0.03-0.25112.0%
Non-GAAP net loss per share, basic-0.04-0.22-82.0%

Income Statement

Three Months Ended June 30, — (in thousands, except per share amounts)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net revenueDiagnostics(1)289,333241,843550,431435,647
Net revenueData and applications(2)93,15372,792180,171134,725
Net revenueTotal net revenue382,486314,635730,602570,372
Cost and operating expensesCost of revenues, diagnostics108,23399,756209,193184,539
Cost and operating expensesCost of revenues, data and applications27,75519,84052,87035,591
Cost and operating expensesTechnology research and development43,92934,48289,85067,873
Cost and operating expensesResearch and development52,63741,619100,87477,493
Cost and operating expensesSelling, general and administrative225,845180,712438,439335,339
Cost and operating expensesTotal cost and operating expenses458,399376,409891,226700,835
Cost and operating expensesLoss from operations-75,913-61,774-160,624-130,463
Cost and operating expensesInterest income3,8971,0937,7632,906
Cost and operating expensesInterest expense-10,283-21,579-24,624-39,582
Cost and operating expensesLoss on debt extinguishment-11,643-11,643
Cost and operating expensesOther income, net102,75741,72975,04814,274
Cost and operating expensesIncome (loss) before (provision for) benefit from income taxes8,815-40,531-114,080-152,865
Cost and operating expenses(Provision for) benefit from income taxes-309-212-24745,968
Cost and operating expensesLosses from equity method investments-2,864-2,100-5,950-3,983
Cost and operating expensesNet income (loss)5,642-42,843-120,277-110,880
Net income (loss) per shareBasic0.03-0.25-0.67-0.64
Net income (loss) per shareDiluted0.03-0.25-0.67-0.64
Weighted-average shares outstanding used to compute net income (loss) per shareBasic179,917173,381179,404171,960
Weighted-average shares outstanding used to compute net income (loss) per shareDiluted182,397173,381179,404171,960
Comprehensive income (loss), net of taxNet income (loss)5,642-42,843-120,277-110,880
Comprehensive income (loss), net of taxForeign currency translation adjustment-1,0333,756-2,8438,354
Comprehensive income (loss), net of taxComprehensive income (loss)4,609-39,087-123,120-102,526

Income Statement

Three Months Ended June 30, — Diagnostics Gross Profit & Gross Margin (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Diagnostics revenue289,333241,843550,431435,647
Cost of revenues, diagnostics108,23399,756209,193184,539
Gross profit, diagnostics181,100142,087341,238251,108
Stock-based compensation expense3,6361,4205,7582,455
Employer payroll tax related to stock-based compensation124254458302
Non-GAAP gross profit, diagnostics184,860143,761347,454253,865
Diagnostics gross margin62.6%58.862.0%57.6
Stock-based compensation expense1.3%0.61.0%0.6
Employer payroll tax related to stock-based compensation0.0%0.10.1%0.1
Non-GAAP gross margin, diagnostics63.9%59.463.1%58.3

Income Statement

Three Months Ended June 30, — Data and applications Gross Profit & Gross Margin

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Data and applications revenue93,15372,792180,171134,725
Cost of revenues, data and applications27,75519,84052,87035,591
Gross profit, data and applications65,39852,952127,30199,134
Stock-based compensation expense9686932,5211,304
Employer payroll tax related to stock-based compensation53114237158
Non-GAAP gross profit, data and applications66,41953,759130,059100,596
Gross margin, data and applications70.2%72.770.7%73.6
Stock-based compensation expense1.0%11.4%1
Employer payroll tax related to stock-based compensation0.1%0.20.1%0.1
Non-GAAP gross margin, data and applications71.3%73.972.2%74.7

Income Statement

Three Months Ended June 30, — Total Gross Profit & Gross Margin

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net revenue382,486314,635730,602570,372
Cost of revenues135,988119,596262,063220,130
Gross profit246,498195,039468,539350,242
Stock-based compensation expense4,6042,1138,2793,759
Employer payroll tax related to stock-based compensation177369695460
Non-GAAP gross profit251,279197,521477,513354,461
Gross margin64.4%6264.1%61.4
Stock-based compensation expense1.2%0.71.1%0.7

Income Statement

Three Months Ended June 30, — Operating Expenses

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Technology research and development43,92934,48289,85067,873
Stock-based compensation expense8,6413,28518,1476,604
Employer payroll tax related to stock-based compensation3584951,170756
Non-GAAP technology research and development34,93030,70270,53360,513
Research and development52,63741,619100,87477,493
Stock-based compensation expense5,2872,3359,8524,317
Employer payroll tax related to stock-based compensation248235731411
Non-GAAP research and development47,10239,04990,29172,765
Selling, general and administrative225,845180,712438,439335,339
Stock-based compensation expense35,58914,72270,54930,749
Employer payroll tax related to stock-based compensation7117742,4565,499
Acquisition related expenses(1)9901,9929865,521
Amortization of intangibles due to acquisition16,60116,77133,47227,927
Franchise taxes related to IPO1,6471,647
Non-GAAP selling, general and administrative171,954144,806330,976263,996
Operating expenses322,411256,813629,163480,705
Stock-based compensation expense49,51720,34298,54841,670
Employer payroll tax related to stock-based compensation1,3171,5044,3576,666
Acquisition related expenses(1)9901,9929865,521
Amortization of intangibles due to acquisition16,60116,77133,47227,927
Franchise taxes related to IPO1,6471,647
Non-GAAP operating expenses253,986214,557491,800397,274

Income Statement

Three Months Ended June 30, — Loss from Operations

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Loss from operations-75,913-61,774-160,624-130,463
Stock-based compensation expense54,12122,455106,82745,429
Employer payroll tax related to stock-based compensation1,4931,8735,0517,126
Acquisition related expenses(1)9901,9929865,521
Franchise taxes related to IPO1,6471,647
Amortization of intangibles due to acquisition16,60116,77133,47227,927
Non-GAAP loss from operations-2,708-17,036-14,288-42,813

Income Statement

Three Months Ended June 30, — Earnings per Share

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income (loss)5,642-42,843-120,277-110,880
Fair value changes(1)-97,401-37,546-66,260-5,696
Stock-based compensation expense54,12122,455106,82745,429
Employer payroll tax related to stock-based compensation1,4931,8735,0517,126
Acquisition related expenses(2)9901,9929865,521
Amortization of intangibles due to acquisition16,60116,77133,47227,927
Losses from equity method investments2,8642,1005,9503,983
Provision for (benefit from) income taxes309212247-45,968
Franchise taxes related to IPO1,6471,647
Amortization of technology license-3,988-3,988-7,977-7,977
Loss on debt extinguishment11,64311,643
Non-GAAP net loss-7,726-37,327-30,338-78,888
Non-GAAP net loss per share, basic-0.04-0.22-0.17-0.46
Weighted average common shares outstanding, basic179,917173,381179,404171,960

Income Statement

Three Months Ended June 30, — Adjusted EBITDA

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income (loss)5,642-42,843-120,277-110,880
Interest income-3,897-1,093-7,763-2,906
Interest expense10,28321,57924,62439,582
Depreciation7,1258,34714,55016,230
Amortization18,86019,68537,61032,155
Provision for (benefit from) income taxes309212247-45,968
EBITDA38,3225,887-51,009-71,787
Losses from equity method investments2,8642,1005,9503,983
Fair value changes(1)-97,401-37,546-66,260-5,696
Stock-based compensation expense54,12122,455106,82745,429
Employer payroll tax related to stock-based compensation1,4931,8735,0517,126
Acquisition related expenses(2)9901,9929865,521
Amortization of technology license-3,988-3,988-7,977-7,977
Franchise taxes related to IPO1,6471,647
Loss on debt extinguishment11,64311,643
Adjusted EBITDA8,044-5,5805,211-21,754

Balance Sheet

June 30, 2026 — (in thousands, except share and per share amounts)

June 30, 2026December 31, 2025
Current AssetsCash and cash equivalents599,614604,787
Current AssetsAccounts receivable(1), net of allowances of $2,794 and $2,755 at June 30, 2026 and December 31, 2025, respectively360,924311,170
Current AssetsInventory53,51251,724
Current AssetsRelated party asset17,5008,785
Current AssetsPrepaid expenses and other current assets42,93840,498
Current AssetsMarketable equity securities216,377150,211
Current AssetsTotal current assets1,290,8651,167,175
Current AssetsProperty and equipment, net89,06689,156
Current AssetsGoodwill470,166470,211
Current AssetsIntangible assets, net312,457349,202
Current AssetsCapitalized software, net19,7726,051
Current AssetsInvestments and other assets17,16421,111
Current AssetsInvestment in joint venture77,81186,557
Current AssetsInvestment in related party8,750

Balance Sheet

(in thousands, except share and per share amounts)

Commitments and contingencies (Note 8)Convertible redeemable preferred stock, $0.0001 par value, 20,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively, no shares issued and outstanding at June 30, 2026 and December 31, 2025$—$—
Stockholders' equityClass A Common Stock, $0.0001 par value, 1,000,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 175,200,077 and 173,235,428 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively1817
Stockholders' equityClass B Common Stock, $0.0001 par value, 5,500,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 5,043,789 issued and outstanding at June 30, 2026 and December 31, 2025, respectively11
Stockholders' equityTreasury Stock, 183,229 shares at June 30, 2026 and December 31, 2025, respectively, at cost-6,642-6,642
Stockholders' equityAdditional Paid-In Capital2,969,6372,892,910
Stockholders' equityAccumulated Other Comprehensive (Loss) Income-1,941902
Stockholders' equityAccumulated deficit-2,516,139-2,395,862
Stockholders' equityTotal Stockholders' equity444,934491,326
Stockholders' equityTotal Liabilities, Convertible redeemable preferred stock, and Stockholders' equity2,365,9112,274,838

Balance Sheet

Six Months Ended June 30, — (in thousands, except per share amounts)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Operating activitiesNet loss-120,277-110,880
Adjustments to reconcile net loss to net cash used in operating activitiesStock-based compensation106,82745,429
Adjustments to reconcile net loss to net cash used in operating activitiesGain on marketable equity securities-66,166-6,007
Adjustments to reconcile net loss to net cash used in operating activitiesLoss on disposal of property and equipment375
Adjustments to reconcile net loss to net cash used in operating activitiesDeferred income taxes-46,216
Adjustments to reconcile net loss to net cash used in operating activitiesLosses from equity method investments5,9503,983
Adjustments to reconcile net loss to net cash used in operating activitiesAmortization of original issue discount3,1251,169
Adjustments to reconcile net loss to net cash used in operating activitiesAmortization of deferred financing fees194332
Adjustments to reconcile net loss to net cash used in operating activitiesChange in fair value of holdback liability-94312
Adjustments to reconcile net loss to net cash used in operating activitiesLoss on debt extinguishment11,643
Adjustments to reconcile net loss to net cash used in operating activitiesDepreciation and amortization52,16148,385
Adjustments to reconcile net loss to net cash used in operating activitiesProvision for bad debt expense866625
Adjustments to reconcile net loss to net cash used in operating activitiesProvision for obsolete inventory400
Adjustments to reconcile net loss to net cash used in operating activitiesNon-cash operating lease costs6,8964,573
Adjustments to reconcile net loss to net cash used in operating activitiesMinimum accretion expense88108
Adjustments to reconcile net loss to net cash used in operating activitiesPIK interest added to principal1,6747,157
Change in assets and liabilitiesAccounts receivable(1)-50,565-49,155
Change in assets and liabilitiesInventory-2,1881,974
Change in assets and liabilitiesPrepaid expenses and other current assets-2,440-188
Change in assets and liabilitiesInvestments and other assets960-11,073
Change in assets and liabilitiesAccounts payable-30,2257,025
Change in assets and liabilitiesRelated party asset2,917
Change in assets and liabilitiesDeferred revenue(2)-12,46736,836
Change in assets and liabilitiesDeferred other income-7,977-7,977
Change in assets and liabilitiesAccrued data licensing fees-1,5683,957
Change in assets and liabilitiesAccrued expenses & other19,9416,991
Change in assets and liabilitiesInterest payable6,2707,122
Change in assets and liabilitiesOperating lease liabilities-7,122-5,942

Cash Flow

Six Months Ended June 30, — (in thousands, except per share amounts)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Investing activitiesPurchases of property and equipment-14,327-9,588
Investing activitiesProceeds from sale of marketable equity securities8,316
Investing activitiesBusiness combinations, net of cash acquired (Note 4)-380,762
Investing activitiesCapitalized software costs-6,832-3,295
Investing activitiesNet cash used in investing activities-21,159-385,329
Financing activitiesProceeds from convertible senior notes, net of initial purchasers' discount443,132
Financing activitiesPrincipal payments on long-term debt-207,717
Financing activitiesPrincipal payments on revolving credit facility-100,000
Financing activitiesPrepayment premium on long-term debt-6,433
Financing activitiesPayment of deferred offering costs-147
Financing activitiesPurchases of capped call-31,234
Financing activitiesProceeds from revolving credit facility, net of original issue discount98,000
Financing activitiesProceeds from long-term debt, net of original issue discount196,000
Financing activitiesPayment of deferred financing fees-751-958
Financing activitiesNet cash provided by financing activities96,850293,042
Financing activitiesEffect of foreign exchange rates on cash-2-37
Financing activitiesNet decrease in Cash, Cash Equivalents and Restricted Cash-5,113-153,784
Financing activitiesCash, cash equivalents and restricted cash, beginning of period609,451341,835
Financing activitiesCash, cash equivalents and restricted cash, end of period604,338188,051
Cash, Cash Equivalents and Restricted Cash are Comprised of:Cash and cash equivalents599,614186,310
Cash, Cash Equivalents and Restricted Cash are Comprised of:Restricted cash and cash equivalents4,7241,741
Cash, Cash Equivalents and Restricted Cash are Comprised of:Total cash, cash equivalents and restricted cash604,338188,051
Supplemental disclosure of cash flow informationCash paid during the year for interest12,29923,980
Supplemental disclosure of cash flow informationCash paid for income taxes247136
Supplemental disclosure of cash flow informationPreferred stock received on accounts receivable(3)8,750$—
Supplemental disclosure of noncash investing and financing activitiesPurchases of property and equipment, accrued but not paid6,1066,863
Supplemental disclosure of noncash investing and financing activitiesRedemption of convertible promissory note20,74314,338
Supplemental disclosure of noncash investing and financing activitiesDeferred financing fees, accrued but not yet paid726545
Supplemental disclosure of noncash investing and financing activitiesDeferred offering costs, accrued but not yet paid12995
Supplemental disclosure of noncash investing and financing activitiesOperating lease liabilities arising from obtaining right-of-use assets360606
Supplemental disclosure of noncash investing and financing activitiesCapitalized software costs, accrued but not yet paid6,564$—
Supplemental disclosure of noncash investing and financing activitiesClass A Common Stock issued in connection with business combinations$—310,320
Supplemental disclosure of noncash investing and financing activitiesConvertible promissory note principal reset due to amendment$—72,488
Full release

Forward Looking Statements... (truncated)expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments, including Tempus' ability to consummate the acquisition of Personalis on the contemplated terms or at all and Tempus’ ability to realize the expected benefits of the acquisition of Paige AI, Ambry Genetics, Deep 6 AI and, if consummated, Personalis; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, trade tensions and tariffs, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“the SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC from time to time. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Investors

Elizabeth Krutoholow

Kendra Webster investorrelations@tempus.com

Media

Kelli Manalli kelli.manalli@tempus.com

Source: Tempus AI, Inc.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Tempus AI earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.